Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PSMC3P1 (Proteasome 26S subunit, ATPase 3 pseudogene 1) is a **pseudogene**, not a protein-coding gene[1]. It is related by sequence to the protein-coding gene PSMC3, which encodes a crucial component of the 26S proteasome complex—a major protein degradation machine in eukaryotic cells[1][3][5]. However, **PSMC3P1 does not encode a functional protein** and lacks evidence for direct biological functions, involvement in diseases, or roles as a therapeutic target. Pseudogenes like PSMC3P1 may have regulatory or evolutionary significance but are not considered drug targets or involved in classic protein-mediated pathways[1]. **Key context:** - PSMC3P1 is a *non-coding pseudogene* and should not be confused with the protein-coding gene **PSMC3** (Proteasome 26S subunit, ATPase 3 / also known as 26S protease regulatory subunit 6A)[1][3][5]. - There is **no evidence or literature supporting PSMC3P1 as a therapeutic target, biomarker, or drug-interactive entity**[1]. - Molecular function, disease association, biomarkers, interacting drugs, and safety concerns are not applicable to pseudogenes without known function[1]. - **If the intention was to inquire about the protein-coding gene PSMC3, refer instead to "Proteasome 26S subunit, ATPase 3" (PSMC3)[3][5].** Sources: - [1] GeneCards: PSMC3P1 – Pseudogene information - [3][5] GeneCards/Wikipedia: PSMC3 – Protein-coding counterpart with detailed molecular function **Summary:** PSMC3P1 is a pseudogene, not a functional protein or therapeutic target; information about biologically relevant roles, pathways, or druggability should refer to its protein-coding counterpart, PSMC3, not this pseudogene[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proteasome 26S subunit, ATPase 3 pseudogene 1 (PSMC3P1).